Senzagen Ab · OMXSTO:SENZA
Senzagen Ab — Investor Presentation (October 2021)
27 slides from Senzagen Ab's investor presentation, Oct 28, 2021
Slide 1: Replacing animal testing with best-in-class in vitro technology
Replacing animal testing with best-in-class in vitro technology 28 October 2021
Slide 2: Disclaimer
Disclaimer This company presentation (the ”Company Presentation”), which is personal to the recipient, is issued by SenzaGen AB (the “Company”). The Company Presentation has been prepared for information purposes only and is not to be relied upon in substitution for the exercise of independent judge
Slide 3: SenzaGen in short
SenzaGen in short Vision Leading technology Business model Growing market • To replace animal testing • Non-animal toxicity testing • Commercialization of • Fast growing market driven with best-in-class in vitro with high quality standard GARD®-platform by multiple secular trends technology, establi
Slide 4: Investment highlights
Investment highlights Accelerating growth strategy through Advancing toward category leadership within non-animal testing on the acquisitions and rapid organic growth back of established GARD®-technology Genomics, machine learning and biology is combined in the Superior accuracy and GARD®-platform r
Slide 5: Agenda: Accelerated growth strategy and acquisition of VitroScreen
I. Accelerated growth strategy II. Acquisition of VitroScreen III. Established market position enabling expansion IV. Fragmented in vitro toxicology testing market V. Experienced Management and Board 5
Slide 6: Accelerated growth strategy
Accelerated growth strategy Targeting category leadership through rapid organic- and acquisition-driven growth Acquisition-driven growth Organic growth 6
Slide 7: Accelerated growth strategy (cont'd)
Accelerated growth strategy (cont’d) Acquisition-driven growth Organic growth Targeting category leadership Drive direct sales and customer retention • Targeting acquisitions of growing and profitable companies • Continue capturing new customers for GARD® with scientific sales and marketing approach
Slide 8: Accelerated growth strategy (cont'd): OECD validation
Accelerated growth strategy (cont’d) OECD validation, enabling new commercial opportunities and acquisitions • Validation enabling expansion – In July 2021, the EU Reference Laboratory for alternatives to animal testing EURL ECVAM, announced their scientific advisory committee ESAC had finalized its
Slide 9: Rapid expansion of regulatory test portfolio
Rapid expansion of regulatory test portfolio Organic expansion of regulatory tests Acquisition driven expansion of regulatory tests Targeted segments through organic expansion Targeted segments through acquisition-driven strategy Phototoxicity Carcinogenicity Genotoxicity Cytotoxicity ADME-Tox Ocula
Slide 10: Agenda: Acquisition of VitroScreen
I. Accelerated growth strategy II. Acquisition of VitroScreen III. Established market position enabling expansion IV. Fragmented in vitro toxicology testing market V. Experienced Management and Board 10
Slide 11: VitroScreen – in vitro specialists
VitroScreen – in vitro specialists Acquisition of VitroScreen VitroScreen in brief • Founded in 2001 by Dr Marisa Meloni, industry expert and an advisor to OECD and other organizations, VitroScreen has two decades of experience and knowledge within the in vitro toxicology and pre-clinical testing in
Slide 12: Acquisition enabling accelerated growth
Acquisition enabling accelerated growth Acquisition rationale Transaction highlights Synergies and cross-selling Portfolio and platform expansion 190% SEK 14.6m • Utilization of respective • Enabling complete toxicology organizations’ sales testing package for regulatory SenzaGen revenue increase to
Slide 13: Combined entities
Combined entities Current SenzaGen Current VitroScreen Combined Non-animal toxicology and leading Innovative non-animal toxicology and Description Non-animal toxicology testing innovation in pre-clinical testing pre-clinical testing Total revenue 8.0 15.61 23.6 FY2020 (SEKm) Total revenue 5.0 9.61 1
Slide 14: Agenda: Established market position enabling expansion
I. Accelerated growth strategy II. Acquisition of VitroScreen III. Established market position enabling expansion IV. Fragmented in vitro toxicology testing market V. Experienced Management and Board 14
Slide 15: The GARD product portfolio
The GARD® product portfolio Established GARD® tests Current GARD®-tests GARD® GARD® GARD® GARD®skin GARD®skin Medical Dose- skin potency air Skin sensitization Device Response GARD®skin GARD®skin Medical Device Cosmetics GARD®potency Chemicals GARD®skin Dose-Response Pharmaceuticals
Slide 16: High performance and broad applicability
High performance and broad applicability Replacing animal testing with reliable human relevant results GARD®: Next generation First generation Traditional testing In vitro In vitro In vivo 90-95% 75-80% 70-75% Accuracy Accuracy Accuracy vs. Human data • Biomarker signatures • Single biomarkers • Not
Slide 17: GARD – attractive test for all industries
GARD® – attractive test for all industries in evaluation of skin and respiratory sensitization High performance Broad applicability Efficiency Ethical • High accuracy, sensitivity • Ability to test a wide range • Short test time: 2 weeks • In vitro = cell-based method and specificity of products and
Slide 18: Geographical presence
Geographical presence Focus on key markets Europe and North America • Markets driven by regulatory demand and increasing community involvement with Europe leading the way • SenzaGen have collaboration and licensing agreements in both North America and Europe • During the year SenzaGen have delivered
Slide 19: Expanding customer base
Expanding customer base Increasing retention with loyal customers • Several international companies that became SenzaGen customers in 2020 continued using GARD® in 2021 • Substantial increase in inquires from new customers during H1 2021 • Based on customer feedback, SenzaGen have expanded the regul
Slide 20: Agenda: Fragmented in vitro toxicology testing market
I. Accelerated growth strategy II. Acquisition of VitroScreen III. Established market position enabling expansion IV. Fragmented in vitro toxicology testing market V. Experienced Management and Board 20
Slide 21: Targeting a fragmented market
Targeting a fragmented market Growing in vitro toxicology testing market Global in vitro toxicology testing market (USDm)1 • Global in vitro market is estimated to be worth approx. Toxicology tests and endpoints 2018 2023 CAGR (%) USD 8.9 billion by 2023, growing 6.8% annually Skin irritation, corro
Slide 22: Market driven by regulatory demand
Market driven by regulatory demand Macro forces providing beneficial market conditions Industry trends and drivers towards non-animal testing • Regulatory • Animal testing bans such as; EU cosmetics ban, ISO 19993 standard (aimed at reducing and replace animal testing) and state laws in US banning a
Slide 23: Agenda: Experienced Management and Board
I. Accelerated growth strategy II. Acquisition of VitroScreen III. Established market position enabling expansion IV. Fragmented in vitro toxicology testing market V. Experienced Management and Board 23
Slide 24: Experienced Management team
Experienced Management team Peter Nählstedt Anna Chérouvrier Hansson Tina Dackemark Lawesson Marianne Olsson CEO VP Sales & Business Dev. VP Marketing & Communications VP Finance Peter has broad commercial Anna has an extensive Tina has long experience Marianne has during the last and leadership exp
Slide 25: Well-renowned Board of Directors
Well-renowned Board of Directors Carl Borrebaeck Anki Malmborg Hager Paul Yianni Laura Chirica Chairman & founder Director Director Director Carl is the founder of Anki has extensive experience Paul brings 30+ years of Laura has 20+ years of SenzaGen and several other as an entrepreneur and CEO lead
Slide 26: Investment highlights
Investment highlights Accelerating growth strategy through Advancing toward category leadership within non-animal testing on the acquisitions and rapid organic growth back of established GARD®-technology Genomics, machine learning and biology is combined in the Superior accuracy and GARD®-platform r
Slide 27: Thank you!
Thank you!